Indirect costs were assessed in an incident cohort study, which was conducted in Spain reporting the economic burden of mTNBC in Spain was substantial but varies by HER2 and HR status of breast tumors over 5 years [40]. The gene discussed is ERBB2; the disease is breast neoplasm.